Abstract
IntroductionThe management and treatment of intracranial aneurysms have substantially evolved with advancements in neuroendovascular technologies. Among the latest developments are the Target(®) Tetra™ coils (Stryker Neurovascular, Kalamazoo, MI, USA). In this non-industry funded illustrated case series we examine the efficacy and safety of Target(®) Tetra™ and describe nuances of their usage.MethodsA retrospective two-centre study examined the usage and outcomes of Target(®) Tetra™ coil usage in a consecutive series of ruptured and unruptured aneurysms. Data was collected on clinical, technical, and imaging characteristics associated with their usage.ResultsThe dataset consisted of information from a total of 75 patients and 80 aneurysms (mean age 55.7 years). 56/75 (74.7%) aneurysms were treated in the setting of aneurysmal subarachnoid haemorrhage. 80/80 (100%) of the aneurysm treatments were technically successful. 2/80 (2.5%) of the cases encountered technical issues, with 1/80 (1.2%) case of coil migration and 1/80 (1.2%) case where the coil could not be detached. The median clinical follow-up time was 5 months. All-cause mortality was 8%, all occurring in ruptured aneurysms. There was 1/75 (1.3%) rebleed at the time of follow-up. 45% aneurysms patients had imaging follow-up at a median of 5 months. Excluding treatments involving stenting, flow-diversion, and intra-saccular devices the adequate occlusion rate at follow-up was 19/21 (90.5%) for ruptured and 6/6 (100%) for unruptured aneurysms, with an overall rate of 25/27 (92.6%).ConclusionsInitial short-term results suggest the safety and efficacy of the Tetra™ coils. Long-term outcomes in terms of aneurysm occlusion require further study.